Blog

Agenda 9:00 am Welcome and Opening Remarks Tao Wu, PhD, President, SABPA Yi Liu, PhD, Chair, BioPharmaCommittee, SABPA; CEO, Kumqat Biosciences 9:15 am Floyd Romesberg, PhD Fellow, Sanofi Presentation: “A semi-synthetic organism that stores and retrieves increased genetic information” 9:45 am Anthony Sun, PhD Presentation: “So you want to start a biotech?The Zentalis Story fromRead more

During September 2 to 7, the 2021 China International Fair for Trade in Services (CIFTIS) co-sponsored by the Ministry of Commerce and the Beijing Municipal Government was held in Beijing.  In the service demonstration case selection, Shanghai Medicilon Inc. (Medicilon) “Internet + One-Stop Preclinical R&D Service Platform” was awarded the “Science and Technology Innovation ServiceRead more

Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department. Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department Dr. Hong Wan, PhD in analytical chemistry from Stockholm University, Sweden, has more than 20 years’ experience in Drug Discovery andRead more

Recently, Loxo Oncology, a research and development group of Eli Lilly, and Kumquat Biosciences (Kumquat) announced that the two parties have reached an exclusive collaboration agreement to jointly discover, develop and commercialize a series of innovative small molecule drug candidates that cause tumor-specific immune responses. As a collaborative partner of Kumquat, Shanghai Medicilon Inc. (Medicilon)Read more

On August 4, 2021, Mr. Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team visited Shanghai Medicilon Inc. (Medicilon) at Chuansha Park for examination.  Professor Shuangqing Peng, CSO of Medicilon; Yaoliang Zhang, Director of the Administration Department; and Nanmei Zhou, Director of the Public Affairs accompanied the examination and organizedRead more

Recently, Shanghai Ringene Biopharma (Ringene) announced that the company’s self-developed anti-tumor class I new drug SHP2 allosteric inhibitor RG001 tablet has been approved for clinical use. Shanghai Medicilon Inc. (Medicilon) provides a range of preclinical services from drug targets to IND filing in the development of RG001 tablets to enter the clinical trial phase, includingRead more

On July 28, 2021, the Class 1 innovative drug LDS tablets developed by Shanghai Leado Pharma Technology Co., Ltd. (Leado Pharma) received the National Medical Products Administration (NMPA) Clinical Trial Approval Notice. Shanghai Medicilon Inc. (Medicilon) provided a full set of preclinical research services including pharmacokinetics and safety evaluation in the development of LDS tablets. Read more

When AI accurately predicts the “difficult” protein 3D structure; When AI completes the new drug design within 21 days; When AI discovers a new mechanism of idiopathic pulmonary fibrosis drugs.  Cutting-edge technology is driving the innovation revolution.  With the empowerment of AI, how will the future of “smart” medicine evolve? On June 18, the 12thRead more

On June 2, 2021, the National Medical Products Administration (NMPA) officially announced that the glucocorticoid drug PA9159 nasal spray was approved for clinical use. The PA9159 developed by Zhejiang Palaatu Pharmaceutical Company (Palaatu) is for seasonal and perennial allergic rhinitis. Class 1 new drug PA9159 for rhinitis In addition, Palaatu plans to submit the clinicalRead more

Safety assessment lab of process chemistry In the research and development process of innovative drugs, the chemical process research of drugs plays a pivotal role.  During the synthesis process to the scale up process in the laboratory, it is not only about output, but also various errors and risks.  Therefore, in the development of innovativeRead more